Multicancer assays leverage cfDNA methylation patterns to detect malignancy and infer tumor origin, with reported tissue-of-origin prediction approaching 87% accuracy in real-world experience. The 142 ...
Many people know that finding cancer early, before it spreads, may help increase the chances of treating and surviving cancer ...
Strategic partnership delivers scalable, CLIA-certified capillary blood testing to support rural Medicaid programs and ...
BioLabs (Nasdaq: AIDX), an early market entrant in cutting-edge, AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today provided an ...
C2N Diagnostics, LLC (“C2N”), a specialty diagnostics company with a vision to bring Clarity Through Innovation®, has reached ...
New data supports GraftAssure commercialization efforts Multi-center study featured 249 biopsy-matched patients Proprietary “Combination Model” ...
By Sneha S K March 3 (Reuters) - Diagnostics firm Droplet Biosciences said on Tuesday it is collaborating with Nvidia to use ...
C2N Diagnostics, LLC ("C2N"), a specialty diagnostics company with a vision to bring Clarity Through Innovation(R), has reached an agreement with BeauBrain Healthcare that brings its breakthrough ...
Codex Genetics, a leading precision diagnostics company headquartered in Hong Kong, today announces a strategic collaboration ...
Illumina, Inc. (NASDAQ: ILMN) today announced that Illumina Laboratory Services, Illumina's CLIA-certified laboratory, is ...
Parents can now access laboratory-based IgE and IgG4 testing for children nationwide Our platform provides a structured ...
Provisional license allows Rapid Novor to begin testing Canadian patients using a highly sensitive, non-invasive blood-based assay for measurable residual disease (MRD) monitoring. KITCHENER, ON, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results